Turning the respiratory flexibility of Mycobacterium tuberculosis against itself

Nature Communications

Volumn 7, Issue , 2016, Pages

  Lamprecht, Dirk A ^a   Finin, Peter M ^a,b   Rahman, Md Aejazur ^a   Cumming, Bridgette M ^a   Russell, Shannon L ^a   Jonnala, Surendranadha R ^c   Adamson, John H ^a   Steyn, Adrie J C ^a,d,e  

^a AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BEDAQUILINE; CLOFAZIMINE; IMIDAZOPYRIDINE DERIVATIVE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; Q 203; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 6-CHLORO-2-ETHYL-N-(4-(4-(4-(TRIFLUOROMETHOXY)PHENYL)PIPERIDIN-1-YL)BENZYL) IMIDAZO(1,2-A)PYRIDINE-3-CARBOXAMIDE; IMIDAZOLE DERIVATIVE; MULTIENZYME COMPLEX; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

BACTERIUM; DRUG; ELECTRON; OXYGEN; RESPIRATION; TUBERCULOSIS; VULNERABILITY;

ANTIBIOTIC THERAPY; ARTICLE; DRUG TARGETING; ELECTRON TRANSPORT; ENZYME INHIBITION; IN VITRO STUDY; MEMBRANE POTENTIAL; MICROBIAL RESPIRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTON TRANSPORT; RESPIRATORY CHAIN; ANIMAL; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DRUG EFFECT; HEP-G2 CELL LINE; HUMAN; IC50; MACROPHAGE; METABOLISM; MICROBIOLOGY; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION; PHYSIOLOGY; PROCEDURES; RAW 264.7 CELL LINE; SYNTHESIS;

EUKARYOTA; MYCOBACTERIUM TUBERCULOSIS;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; DIARYLQUINOLINES; DRUG THERAPY, COMBINATION; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; HEP G2 CELLS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MACROPHAGES; MICE; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PIPERIDINES; PYRIDINES; RAW 264.7 CELLS; REACTIVE OXYGEN SPECIES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84981492969     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12393     Document Type: Article

References (64)

1. WHO. Global tuberculosis report http: //www. who. int/tb/publications/ global-report/en/ (2015).
2. Mitnick, C. D. et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med. 359, 563-574 (2008).
3. Zumla, A., Raviglione, M., Hafner, R. a&Fordham von Reyn, C. Tuberculosis. NEJM 368, 745-755 (2013).
4. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis WHO guidelines approved by the guidelines review committee http: //www. ncbi. nlm. nih. gov/books/NBK247420/ (2014).
5. Management of MDR-TB: a field guide: a companion document to guidelines for programmatic management of drug-resistant tuberculosis: integrated management of adolescent and adult illness (IMAI) WHO guidelines approved by the guidelines review committee http: //apps. who. int/iris/handle/10665/ 44163 (2009).
6. Cook, G. M., Hards, K., Vilchèze, C., Hartman, T. a&Berney, M. Energetics of respiration and oxidative phosphorylation in mycobacteria. Microbiol. Spectr. 2, http: //dx. doi. org/10. 1128/microbiolspec. MGM2-0015-2013 (2014).
7. Watanabe, S. et al. Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog. 7, e1002287 (2011).
8. Rao, S. P. S., Alonso, S., Rand, L., Dick, T. a&Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 105, 11945-11950 (2008).
9. Bald, D. a&Koul, A. Respiratory ATP synthesis: the new generation of mycobacterial drug targets? FEMS Microbiol. Lett. 308, 1-7 (2010).
10. Arora, K. et al. Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58, 6962-6965 (2014).
11. Preiss, L. et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci. Adv. 1, e1500106 (2015).
12. Matteelli, A., Carvalho, A. C., Dooley, K. E. a&Kritski, A. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 5, 849-858 (2010).
13. Koul, A. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273-25280 (2008).
14. Koul, A. et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat. Commun. 5, 3369 (2014).
15. Berney, M., Hartman, T. E. a&Jacobs, W. R. A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline. mBio 5, e01275-01214 (2014).
16. Hards, K. et al. Bactericidal mode of action of bedaquiline. J. Antimicrob. Chemother. 70, 2028-2037 (2015).
17. Pethe, K. et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19, 1157-1160 (2013).
18. Barry, V. C. et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 179, 1013-1015 (1957).
19. Yano, T. et al. Reduction of clofazimine by mycobacterial type 2 NADH: quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J. Biol. Chem. 286, 10276-10287 (2011).
20. Grosset, J. H. et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am. J. Respir. Crit. Care Med. 188, 608-612 (2013).
21. Diacon, A. H. et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am. J. Respir. Crit. Care Med. 191, 943-953 (2015).
22. Van Deun, A. et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182, 684-692 (2010).
23. Tyagi, S. et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc. Natl Acad. Sci. USA 112, 869-874 (2015).
24. Berg, J. M., Tymoczko, J. L. a&Stryer, L. Biochemistry. 5th edn, p. 587 (W. H. Freeman and Company, 2002).
25. Sanwal, B. D. Allosteric controls of amphilbolic pathways in bacteria. Bacteriol. Rev. 34, 20-39 (1970).
26. Ferrick, D. A., Neilson, A. a&Beeson, C. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov. Today 13, 268-274 (2008).
27. Saini, V. et al. Ergothioneine maintains redox and bioenergetic homeostasis essential for drug susceptibility and virulence of Mycobacterium tuberculosis. Cell Rep. 14, 572-585 (2015).
28. Zhang, J. et al. Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells. Nat. Protoc. 7, 1068-1085 (2012).
29. Carreau, A., Hafny-Rahbi, B. E., Matejuk, A., Grillon, C. a&Kieda, C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J. Cell. Mol. Med. 15, 1239-1253 (2011).
30. Arora, K. et al. Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58, 6962-6965 (2014).
31. Wilcox, C. S. a&Pearlman, A. Chemistry and antihypertensive effects of tempol and other nitroxides. Pharmacol. Rev. 60, 418-469 (2008).
32. Aruoma, O. I., Halliwell, B., Hoey, B. M. a&Butler, J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med. 6, 593-597 (1989).
33. Benrahmoune, M., Therond, P. a&Abedinzadeh, Z. The reaction of superoxide radical with N-acetylcysteine. Free Radic. Biol. Med. 29, 775-782 (2000).
34. Larsson, C., Påhlman, I.-L. a&Gustafsson, L. The importance of ATP as a regulator of glycolytic flux in Saccharomyces cerevisiae. Yeast 16, 797-809 (2000).
35. Kemp, R. G. a&Foe, L. G. Allosteric regulatory properties of muscle phosphofructokinase. Mol. Cell. Biochem. 57, 147-154 (1983).
36. Jetten, M. S., Gubler, M. E., Lee, S. H. a&Sinskey, A. J. Structural and functional analysis of pyruvate kinase from Corynebacterium glutamicum. Appl. Environ. Microbiol. 60, 2501-2507 (1994).
37. Koebmann, B. J., Westerhoff, H. V., Snoep, J. L., Nilsson, D. a&Jensen, P. R. The glycolytic flux in Escherichia coli is controlled by the demand for ATP. J. Bacteriol. 184, 3909-3916 (2002).
38. Holm, A. K. et al. Metabolic and transcriptional response to cofactor perturbations in Escherichia coli. J. Biol. Chem. 285, 17498-17506 (2010).
39. Sekine, H. et al. H-ATPase defect in Corynebacterium glutamicum abolishes glutamic acid production with enhancement of glucose consumption rate. Appl. Microbiol. Biotechnol 57, 534-540 (2001).
40. Mitchell, P. Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. Biol. Rev. Camb. Philos. Soc. 41, 445-502 (1966).
41. Hong, S. a&Pedersen, P. L. ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas. MMBR 72, 590-641 (2008).
42. Jensen, P. R. a&Michelsen, O. Carbon and energy metabolism of atp mutants of Escherichia coli. J. Bacteriol. 174, 7635-7641 (1992).
43. Russell, J. B. The energy spilling reactions of bacteria and other organisms. J. Mol. Microbiol. Biotechnol. 13, 1-11 (2007).
44. Russell, J. B. a&Cook, G. M. Energetics of bacterial growth: balance of anabolic and catabolic reactions. Microbiol. Rev. 59, 48-62 (1995).
45. Kadenbach, B. Intrinsic and extrinsic uncoupling of oxidative phosphorylation. Biochim. Biophys. Acta 1604, 77-94 (2003).
46. Skulachev, V. P. Uncoupling: new approaches to an old problem of bioenergetics. Biochim. Biophys. Acta 1363, 100-124 (1998).
47. Kusumoto, K., Sakiyama, M., Sakamoto, J., Noguchi, S. a&Sone, N. Menaquinol oxidase activity and primary structure of cytochrome bd from the amino-acid fermenting bacterium Corynebacterium glutamicum. Arch. Microbiol. 173, 390-397 (2000).
48. Mason, M. G. et al. Cytochrome bd confers nitric oxide resistance to Escherichia coli. Nat. Chem. Biol. 5, 94-96 (2009).
49. Borisov, V. B., Gennis, R. B., Hemp, J. a&Verkhovsky, M. I. The cytochrome bd respiratory oxygen reductases. Biochim. Biophys. Acta 1807, 1398-1413 (2011).
50. Oliva, B., O'Neill, A. J., Miller, K., Stubbings, W. a&Chopra, I. Antistaphylococcal activity and mode of action of clofazimine. J. Antimicrob. Chemother. 53, 435-440 (2004).
51. Schurig-Briccio, L. A., Yano, T., Rubin, H. a&Gennis, R. B. Characterization of the type 2 NADH: menaquinone oxidoreductases from Staphylococcus aureus and the bactericidal action of phenothiazines. Biochim. Biophys. Acta 1837, 954-963 (2014).
52. Balemans, W. et al. Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria. Antimicrob. Agents Chemother. 56, 4131-4139 (2012).
53. Sambandamurthy, V. K. et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat. Med. 8, 1171-1174 (2002).
54. Global Alliance for TB Drug Development. TMC-207. Tuberculosis; 88: 168-169 (2008).
55. Diacon, A. H. et al. The Diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397-2405 (2009).
56. Global Alliance for TB Drug Development. Clofazimine. Tuberculosis 88, 96-99 (2008).
57. Global Alliance for TB Drug Development. Rifampin. Tuberculosis 88, 151-154 (2008).
58. Global Alliance for TB Drug Development. Ethambutol. Tuberculosis 88, 102-105 (2008).
59. Global Alliance for TB Drug Development. Isoniazid. Tuberculosis 88, 112-116 (2008).
60. Global Alliance for TB Drug Development. Streptomycin. Tuberculosis 88, 162-163 (2008).
61. Global Alliance for TB Drug Development. Moxifloxacin. Tuberculosis 88, 127-131 (2008).
62. Kang, S. et al. Lead optimization of a novel series of imidazo[1, 2-a]pyridine amides leading to a clinical candidate (Q203) as a multi-and extensively-drugresistant anti-tuberculosis agent. J. Med. Chem. 57, 5293-5305 (2014).
63. Pringle, M. J., Kenneally, M. K. a&Joshi, S. ATP synthase complex from bovine heart mitochondria. Passive H conduction through F0 does not require oligomycin sensitivity-conferring protein. J. Biol. Chem. 265, 7632-7637 (1990).
64. Schwalbe, R., Steele-Moore, L. a&Goodwin, A. C. Antimicrobial Susceptibility Testing Protocols 68 (CRC Press, 2007).